Logo image of STOK

STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis

USA - NASDAQ:STOK - US86150R1077 - Common Stock

32.28 USD
+0.59 (+1.86%)
Last: 10/24/2025, 8:00:00 PM
32.28 USD
0 (0%)
After Hours: 10/24/2025, 8:00:00 PM
Fundamental Rating

5

Taking everything into account, STOK scores 5 out of 10 in our fundamental rating. STOK was compared to 534 industry peers in the Biotechnology industry. STOK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. STOK has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year STOK was profitable.
In the past year STOK had a positive cash flow from operations.
STOK had negative earnings in each of the past 5 years.
In the past 5 years STOK always reported negative operating cash flow.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With an excellent Return On Assets value of 13.65%, STOK belongs to the best of the industry, outperforming 95.13% of the companies in the same industry.
STOK has a better Return On Equity (15.67%) than 94.76% of its industry peers.
STOK's Return On Invested Capital of 9.20% is amongst the best of the industry. STOK outperforms 93.82% of its industry peers.
Industry RankSector Rank
ROA 13.65%
ROE 15.67%
ROIC 9.2%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

STOK has a better Profit Margin (26.26%) than 95.88% of its industry peers.
With an excellent Operating Margin value of 20.15%, STOK belongs to the best of the industry, outperforming 94.57% of the companies in the same industry.
Industry RankSector Rank
OM 20.15%
PM (TTM) 26.26%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

8

2. Health

2.1 Basic Checks

STOK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for STOK has been increased compared to 1 year ago.
The number of shares outstanding for STOK has been increased compared to 5 years ago.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 21.54 indicates that STOK is not in any danger for bankruptcy at the moment.
STOK has a Altman-Z score of 21.54. This is amongst the best in the industry. STOK outperforms 91.39% of its industry peers.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 21.54
ROIC/WACC0.98
WACC9.36%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

STOK has a Current Ratio of 6.98. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
STOK has a better Current ratio (6.98) than 69.10% of its industry peers.
STOK has a Quick Ratio of 6.98. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of STOK (6.98) is better than 69.48% of its industry peers.
Industry RankSector Rank
Current Ratio 6.98
Quick Ratio 6.98
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 142.58% over the past year.
The Revenue has grown by 1218.65% in the past year. This is a very strong growth!
EPS 1Y (TTM)142.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)1218.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.01%

3.2 Future

The Earnings Per Share is expected to grow by 16.02% on average over the next years. This is quite good.
Based on estimates for the next years, STOK will show a very strong growth in Revenue. The Revenue will grow by 68.28% on average per year.
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%
EPS Next 5Y16.02%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y68.28%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 34.71, which means the current valuation is very expensive for STOK.
STOK's Price/Earnings ratio is rather cheap when compared to the industry. STOK is cheaper than 92.88% of the companies in the same industry.
STOK is valuated rather expensively when we compare the Price/Earnings ratio to 26.89, which is the current average of the S&P500 Index.
STOK is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 34.71
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, STOK is valued cheaply inside the industry as 92.32% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, STOK is valued cheaper than 94.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 28.93
EV/EBITDA 32.53
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
STOK's earnings are expected to decrease with -16.29% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%

0

5. Dividend

5.1 Amount

STOK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

STOKE THERAPEUTICS INC

NASDAQ:STOK (10/24/2025, 8:00:00 PM)

After market: 32.28 0 (0%)

32.28

+0.59 (+1.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11
Inst Owners118.79%
Inst Owner Change0.5%
Ins Owners4.3%
Ins Owner Change-28.1%
Market Cap1.77B
Revenue(TTM)199.89M
Net Income(TTM)52.48M
Analysts84.71
Price Target24.71 (-23.45%)
Short Float %20.59%
Short Ratio9.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)291.04%
Min EPS beat(2)23.41%
Max EPS beat(2)558.67%
EPS beat(4)4
Avg EPS beat(4)165.54%
Min EPS beat(4)13.51%
Max EPS beat(4)558.67%
EPS beat(8)8
Avg EPS beat(8)88.85%
EPS beat(12)11
Avg EPS beat(12)62.04%
EPS beat(16)12
Avg EPS beat(16)29.4%
Revenue beat(2)2
Avg Revenue beat(2)863.06%
Min Revenue beat(2)52.02%
Max Revenue beat(2)1674.1%
Revenue beat(4)4
Avg Revenue beat(4)546.83%
Min Revenue beat(4)43.23%
Max Revenue beat(4)1674.1%
Revenue beat(8)7
Avg Revenue beat(8)280.95%
Revenue beat(12)10
Avg Revenue beat(12)183.53%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.04%
EPS NY rev (1m)0%
EPS NY rev (3m)384.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.87%
Valuation
Industry RankSector Rank
PE 34.71
Fwd PE N/A
P/S 8.85
P/FCF 28.93
P/OCF 28.72
P/B 5.28
P/tB 5.28
EV/EBITDA 32.53
EPS(TTM)0.93
EY2.88%
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)1.12
FCFY3.46%
OCF(TTM)1.12
OCFY3.48%
SpS3.65
BVpS6.11
TBVpS6.11
PEG (NY)0.3
PEG (5Y)N/A
Graham Number11.31
Profitability
Industry RankSector Rank
ROA 13.65%
ROE 15.67%
ROCE 11.65%
ROIC 9.2%
ROICexc 32.43%
ROICexgc 32.43%
OM 20.15%
PM (TTM) 26.26%
GM N/A
FCFM 30.59%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 22.67%
Cap/Sales 0.23%
Interest Coverage 250
Cash Conversion 145.71%
Profit Quality 116.5%
Current Ratio 6.98
Quick Ratio 6.98
Altman-Z 21.54
F-Score8
WACC9.36%
ROIC/WACC0.98
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)142.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%
EPS Next 5Y16.02%
Revenue 1Y (TTM)1218.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.01%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y68.28%
EBIT growth 1Y135.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.74%
EBIT Next 3Y-11.06%
EBIT Next 5Y21.61%
FCF growth 1Y167.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y170.32%
OCF growth 3YN/A
OCF growth 5YN/A

STOKE THERAPEUTICS INC / STOK FAQ

What is the fundamental rating for STOK stock?

ChartMill assigns a fundamental rating of 5 / 10 to STOK.


What is the valuation status for STOK stock?

ChartMill assigns a valuation rating of 4 / 10 to STOKE THERAPEUTICS INC (STOK). This can be considered as Fairly Valued.


Can you provide the profitability details for STOKE THERAPEUTICS INC?

STOKE THERAPEUTICS INC (STOK) has a profitability rating of 4 / 10.


What is the valuation of STOKE THERAPEUTICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for STOKE THERAPEUTICS INC (STOK) is 34.71 and the Price/Book (PB) ratio is 5.28.